Key facts
- This page summarizes Michael Sinclair's Form 4 filing for OPIANT PHARMACEUTICALS, INC..
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 06 Jun 2022, 16:57.
Michael Sinclair - 02 Jun 2022 Form 4 Insider Report for OPIANT PHARMACEUTICALS, INC.
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 02 Jun 2022
- Net transaction value
- -$274,623
- SEC form
- 4
- Accepted by SEC
- 06 Jun 2022, 16:57:59 UTC
- Prior SEC filing
- 25 Aug 2021
- Next SEC filing
- 08 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael Sinclair
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael Sinclair filed Form 4 for OPIANT PHARMACEUTICALS, INC. on 06 Jun 2022.
Change
- Previous filing in this sequence was filed on 25 Aug 2021.
- Current net transaction value: -$274,623.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
OPNT
transaction
Common Stock
Sale
- Transaction value
- $135,136
- Shares
- -9,736
- Change %
- -14%
- Price
- $13.88
- Shares after
- 59,484
- Date
- 02 Jun 2022
- Ownership
- Direct
OPNT
transaction
Common Stock
Sale
- Transaction value
- $139,488
- Shares
- -10,264
- Change %
- -17%
- Price
- $13.59
- Shares after
- 49,220
- Date
- 03 Jun 2022
- Ownership
- Direct
* marks a reported price that did not pass the local price check.